Company intelligence / Profile preview

Oerth Bio

Durham, North Carolina, United Statesoerthbio.com ↗

Ownership: Private
Employees: ~30
Development stage: Preclinical

Overview

Oerth Bio has developed a proprietary agricultural PROTAC® platform for targeted protein degradation in plants. The company remains pre-commercial with no public clinical results but has met initial milestones in its collaboration with Bayer. Its technology aims to deliver highly selective crop protection solutions with lower environmental impact.

Therapeutic areas: Other
Modalities: Small molecules (PROTAC® protein degraders/proteolysis-targeting chimeras)
Industry: Agriculture & AgTech

Partnerships

Bayer (major R&D/collaboration partner since founding)Arvinas (technology originator/co-founder)

Beyond the preview

Go deeper on Oerth Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oerth Bio.

Explore the full profile